Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

• Published in: Frontiers in immunology Vol. 13; p. 956907
• Main Authors: Chitnis, Tanuja, Kaskow, Belinda J., Case, Junning, Hanus, Katherine, Li, Zhenhua, Varghese, Johnna F., Healy, Brian C., Gauthier, Christian, Saraceno, Taylor J., Saxena, Shrishti, Lokhande, Hrishikesh, Moreira, Thais G., Zurawski, Jonathan, Roditi, Rachel E., Bergmark, Regan W., Giovannoni, Federico, Torti, Maria F., Li, Zhaorong, Quintana, Francisco, Clementi, William A., Shailubhai, Kunwar, Weiner, Howard L., Baecher-Allan, Clare M.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.11.2022
• Subjects: Administration, Intranasal; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; CD8+ T cells; CD8-Positive T-Lymphocytes; Foralumab; Humans; Immunology; immunomodulation; Muromonab-CD3; nasal anti-CD3; Research Subjects; Tregs; immunomodulation; CD8+ T cells; Foralumab; nasal anti-CD3; Tregs

Parenteral anti-CD3 Mab (OKT3) has been used to treat transplant rejection and parental administration of a humanized anti-CD3 Mab (Teplizumab) showed positive effects in diabetes. Nasal administration of anti-CD3 Mab has not been carried out in humans. Nasal anti-CD3 Mab suppresses autoimmune disea...